StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock.
Ayala Pharmaceuticals Stock Performance
ADXS stock opened at $0.56 on Wednesday. The firm has a market cap of $5.97 million, a price-to-earnings ratio of -0.07 and a beta of 1.62. The firm has a 50-day simple moving average of $0.69 and a two-hundred day simple moving average of $0.74. Ayala Pharmaceuticals has a one year low of $0.50 and a one year high of $1.95.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last released its quarterly earnings results on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Recommended Stories
- Five stocks we like better than Ayala Pharmaceuticals
- The How and Why of Investing in Biotech Stocks
- MarketBeat Week in Review – 4/22 – 4/26
- EV Stocks and How to Profit from Them
- 3 Stocks Leading the U.S. Agriculture Comeback
- Russell 2000 Index, How Investors Use it For Profitable Trading
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
